KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $53.6 million.

  • Halozyme Therapeutics' Other Non-Current Assets fell 3355.63% to $53.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $53.6 million, marking a year-over-year decrease of 3355.63%. This contributed to the annual value of $53.6 million for FY2025, which is 3355.63% down from last year.
  • Halozyme Therapeutics' Other Non-Current Assets amounted to $53.6 million in Q4 2025, which was down 3355.63% from $55.7 million recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' Other Non-Current Assets peaked at $80.6 million during Q4 2024, and registered a low of $13.4 million during Q4 2021.
  • Over the past 5 years, Halozyme Therapeutics' median Other Non-Current Assets value was $25.8 million (recorded in 2022), while the average stood at $35.4 million.
  • In the last 5 years, Halozyme Therapeutics' Other Non-Current Assets surged by 34245.65% in 2024 and then tumbled by 3355.63% in 2025.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Other Non-Current Assets stood at $13.4 million in 2021, then soared by 96.07% to $26.3 million in 2022, then tumbled by 31.12% to $18.1 million in 2023, then skyrocketed by 344.91% to $80.6 million in 2024, then crashed by 33.56% to $53.6 million in 2025.
  • Its Other Non-Current Assets was $53.6 million in Q4 2025, compared to $55.7 million in Q3 2025 and $56.4 million in Q2 2025.